Brief: Active Biotech Regains Global Rights To Development And Commercialization Of Laquinimod

Active Biotech AB publ

05/09/2018 07:34

Sept 5 (Reuters) - Active Biotech AB  ACTI.ST :
    * ACTIVE BIOTECH REGAINS GLOBAL RIGHTS TO DEVELOPMENT AND
COMMERCIALIZATION OF LAQUINIMOD
    * TEVA'S DECISION TO RETURN THE RIGHTS IS BASED ON THE FACT
THAT
TEVA DOES NOT INTEND TO CONTINUE THE CLINICAL DEVELOPMENT OF
LAQUINIMOD

Source text for Eikon:  ID:nGNE5ZZbJw 
Further company coverage:  ACTI.ST 

 (Reporting by Stockholm Newsroom)
 ((stockholm.newsroom@thomsonreuters.com; +4687001017;))